Convergent Ablation Plus Left Atrial Appendage Isolation for the Treatment of Persistent Atrial Fibrillation
Recruiting · NCT06165510 · Interventional (participants receive a specific treatment) · Lead sponsor: Barts & The London NHS Trust
View the official record on ClinicalTrials.gov →Interventions studied
Epicardial AF ablation using AtriCure EPi-Sense-AF Guided Coagulation System with Left Atrial Appendage Exclusion using the AtriCure LARIAT Suture Delivery Device.Standard Endocardial Catheter Ablation
What this trial is about
A randomised controlled clinical trial to assess efficacy of convergent ablation with the LARIAT procedure, as compared to standard endocardial catheter ablation in patients with long-standing persistent atrial fibrillation (AF).
Who can take part
Age range
18 Years to 80 Years
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Age \> 18 years; \< 80 years
- Persistent AF \> 1-year duration
- Left atrium size \< 6cm
- Pts should be able to provide written informed consent.
Exclusion criteria
- Subjects currently enrolled in another investigational study except in case of observational registry with no associated treatments.
- Subject has a reversible cause of AF or transient AF
- Subject is absent of LAA or if the LAA is previously surgically ligated
- Subject has had previous cardiac surgery or abdominal surgery.
- Subject has contraindication to anticoagulation.
- Patients with hypertrophic cardiomyopathy.
- Patients with significant valve disease.
- Subject has had previous catheter or surgical ablation
Where it is running
1 location listed.
- St Bartholomew's Hospital - London, United Kingdom